Carl Zeiss Meditec Remains on Growth Course
(Thomson Reuters ONE) -
Carl Zeiss Meditec AG /
Carl Zeiss Meditec Remains on Growth Course
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Revenues increased by 17.1 percent over previous year - double-digit growth
rates in all three strategic business units - positive performance in Japan
Medical technology provider Carl Zeiss Meditec is continuing its successful path
in the 2010/11 fiscal year and has increased both revenues and earnings. All
three strategic business units (SBU) and reporting regions have contributed to
this positive trend.
"After the first half of our fiscal year, we remain optimistic and expect
revenues between 720 and 750 million euros for the entire year," states Dr.
Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
The half-year result for Japan is particularly positive: despite the recent
natural disasters, the company also showed continued stable development in this
region. "I would like to extend a special thanks to the employees there. Without
their extreme efforts, this would hardly have been possible," adds Dr. Monz.
Overview of the key figures
In the first half of the current fiscal year, Carl Zeiss Meditec generated
consolidated revenues of 376.0 million euros (last year: 321.1 million). This
corresponds to an increase of 17.1 percent over the previous year. With double-
digit revenue growth, all three strategic business units contributed to this
positive trend. At 20.6 percent revenue growth, the Microsurgery SBU is the most
successful business unit. Ophthalmic Systems generated revenue growth of 15.9
percent and Surgical Ophthalmology 10.2 percent.
All reporting regions of Carl Zeiss Meditec contributed to revenue growth.
Despite the recent events in Japan, the Asia-Pacific region generated the most
stable and strongest growth at 28.0 percent, followed by the Americas at 16.4
percent and EMEA at 9.1 percent.
Earnings before interest and taxes (EBIT) climbed to 51.3 million euros (last
year: 39.3 million). The EBIT margin improved from 12.2 to 13.6 percent in the
first half of 2010/11.
"We are very satisfied with the results of the first half year, and we are
definitely on the right track." says Dr. Monz. "We are striving for sustained
growth in the individual markets, intend to bring additional customer-oriented
innovations to the market, to expand into new markets and to continue impressing
our customers with excellent services," adds Dr. Monz.
Revenue by strategic business unit
+----------------------+-------------------+------------------+----------------+
|In thousands of euros |6 months |6 months |Change over |
| |2009/10 |2010/11 |previous year |
+----------------------+-------------------+------------------+----------------+
|Ophthalmic Systems |149,564 |173,367 |+15.9% |
+----------------------+-------------------+------------------+----------------+
|Surgical Ophthalmology|41,058 |45,256 |+10.2% |
+----------------------+-------------------+------------------+----------------+
|Microsurgery |130,522 |157,421 |+20.6% |
+----------------------+-------------------+------------------+----------------+
Revenue by Region
+---------------------+-------------------+-------------------+----------------+
|In thousands of euros|6 months |6 months |Change over |
| |2009/10 |2010/11 |previous year |
+---------------------+-------------------+-------------------+----------------+
|EMEA |119,250 |129,996 |+9.0% |
+---------------------+-------------------+-------------------+----------------+
|Americas |106,546 |124,024 |+16.4% |
+---------------------+-------------------+-------------------+----------------+
|Asia/Pacific |95,348 |122,024 |+28.0% |
+---------------------+-------------------+-------------------+----------------+
--- End of Message ---
Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany
WKN: 531370;ISIN: DE0005313704;Index:Prime All Share,TECH All Share,TecDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Carl Zeiss Meditec AG via Thomson Reuters ONE
[HUG#1512707]
Unternehmensinformation / Kurzprofil:
Datum: 05.05.2011 - 07:04 Uhr
Sprache: Deutsch
News-ID 54266
Anzahl Zeichen: 5796
contact information:
Town:
Jena
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 267 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec Remains on Growth Course"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
